For the quarter ending 2026-03-31, TXG made $150,843K in revenue. -$13,470K in net income. Net profit margin of -8.93%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 150,843 | 159,959* | 149,002 | 172,908 |
| Cost of products and services revenue | 44,665 | 54,164* | 48,695 | 47,824 |
| Gross profit | 106,178 | 105,795* | 100,307 | 125,084 |
| Research and development | 56,847 | 61,005* | 57,194 | 61,224 |
| Selling, general and administrative | 66,377 | 91,451* | 75,355 | 74,434 |
| Loss on settlement | 0 | -11,150* | 0 | 40,700 |
| In-process research and development | - | 0* | - | - |
| Total operating expenses | 123,224 | 163,606* | 132,549 | 94,958 |
| Loss from operations | -17,046 | -57,811* | -32,242 | 30,126 |
| Interest income | 5,014 | 5,843* | 5,199 | 4,271 |
| Interest expense | - | 0* | -3 | 3 |
| Other income (expense), net | -815 | -1,127* | -1,165 | 2,603 |
| Total other income | 4,199 | 4,716* | 4,037 | 6,871 |
| Loss before provision for income taxes | -12,847 | -53,095* | -28,205 | 36,997 |
| Provision for income taxes | 623 | 1,048* | -733 | 2,459 |
| Net loss | -13,470 | -54,143 | -27,472 | 34,538 |
| Basic EPS | -0.1 | -0.433 | -0.22 | 0.28 |
| Diluted EPS | -0.1 | -0.436 | -0.22 | 0.28 |
| Basic Average Shares | 128,291,153 | 124,991,955 | 125,502,291 | 123,755,409 |
| Diluted Average Shares | 128,291,153 | 124,237,644 | 125,502,291 | 124,509,720 |
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)